Royal Philips posted €17.83 billion in revenue for 2025, a slight 1% decline year-on-year, alongside a €897 million net profit turnaround from losses in prior years. This recovery reflects Philips’ intensified focus on innovation across its Diagnosis & Treatment, Connected Care, and Personal Health segments, as well as resolution of major Respironics litigation and enhanced operational discipline. Despite improved margins and earnings, risks remain from regulatory compliance and supply chain dynamics. Capital allocation strategies include a proposed dividend hike to €0.85 per share and targeted share repurchases supporting long-term incentive plans. Investors should monitor ongoing execution on AI-enhanced product rollouts, evolving regulatory frameworks, and potential impacts of geopolitical tensions.